Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer
Gomez, Henry L., Philco, Manuel, Pimentel, Patricia, Kiyan, Miriam, Monsalvo, Maria Laura, Conlan, Maureen G., Saikali, Khalil G., Chen, Michael M., Seroogy, Joseph J., Wolff, Andrew A., Escandon, RafVolume:
23
Langue:
english
Journal:
Anti-Cancer Drugs
DOI:
10.1097/cad.0b013e32834e74d6
Date:
March, 2012
Fichier:
PDF, 227 KB
english, 2012